Skip to main content
eScholarship
Open Access Publications from the University of California

UCSF

UC San Francisco Previously Published Works bannerUCSF

SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.

  • Author(s): Ng, Dianna L;
  • Goldgof, Gregory M;
  • Shy, Brian R;
  • Levine, Andrew G;
  • Balcerek, Joanna;
  • Bapat, Sagar P;
  • Prostko, John;
  • Rodgers, Mary;
  • Coller, Kelly;
  • Pearce, Sandra;
  • Franz, Sergej;
  • Du, Li;
  • Stone, Mars;
  • Pillai, Satish K;
  • Sotomayor-Gonzalez, Alicia;
  • Servellita, Venice;
  • Martin, Claudia Sanchez San;
  • Granados, Andrea;
  • Glasner, Dustin R;
  • Han, Lucy M;
  • Truong, Kent;
  • Akagi, Naomi;
  • Nguyen, David N;
  • Neumann, Neil M;
  • Qazi, Daniel;
  • Hsu, Elaine;
  • Gu, Wei;
  • Santos, Yale A;
  • Custer, Brian;
  • Green, Valerie;
  • Williamson, Phillip;
  • Hills, Nancy K;
  • Lu, Chuanyi M;
  • Whitman, Jeffrey D;
  • Stramer, Susan L;
  • Wang, Candace;
  • Reyes, Kevin;
  • Hakim, Jill MC;
  • Sujishi, Kirk;
  • Alazzeh, Fariba;
  • Pham, Lori;
  • Thornborrow, Edward;
  • Oon, Ching-Ying;
  • Miller, Steve;
  • Kurtz, Theodore;
  • Simmons, Graham;
  • Hackett, John;
  • Busch, Michael P;
  • Chiu, Charles Y
  • et al.
Abstract

Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors in early April 2020. We additionally describe the longitudinal dynamics of immunoglobulin-G (IgG), immunoglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients. The median time to seroconversion ranged from 10.3-11.0 days for these 3 assays. Neutralizing antibodies rose in tandem with immunoglobulin titers following symptom onset, and positive percent agreement between detection of IgG and neutralizing titers was >93%. These findings emphasize the importance of using highly accurate tests for surveillance studies in low-prevalence populations, and provide evidence that seroreactivity using SARS-CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of in vitro neutralizing capacity.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View